PMID- 19476018
OWN - NLM
STAT- MEDLINE
DCOM- 20090724
LR  - 20131121
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 19
IP  - 2
DP  - 2009
TI  - Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year 
      experience with 3004 infusions in Iranian patients with primary immunodeficiency 
      diseases.
PG  - 139-45
AB  - Intravenous immunoglobulin (IVIG) replacement therapy improves health-related 
      quality of life in patients with a primary immunodeficiency disease, although 
      there have been reports of adverse reactions associated with its regular 
      administration. The study population was composed of 99 patients with primary 
      antibody deficiencies. All the patients were diagnosed with a primary 
      immunodeficiency disease and received at least 4 infusions of IVIG at the 
      Children's Medical Center Hospital, Tehran, Iran over a 13-year period 
      (1995-2007). A total of 3004 infusions were recorded, and 216 (7.2%) of these 
      were associated with adverse reactions in 66 patients. Adverse reactions were 
      classified as mild (172 reactions), moderate (41 reactions), and severe (3 
      reactions). The rate of adverse reaction varied by diagnosis from 3.35% in 
      patients with X-linked agammaglobulinemia to 17.4% in IgG subclass deficiency. 
      There were no age-related differences in the rates of adverse reactions. Adverse 
      reactions to IVIG infusions are occasionally encountered; therefore, physicians 
      and nurses should be aware of these reactions in order to manage and prevent 
      them.
FAU - Dashti-Khavidaki, S
AU  - Dashti-Khavidaki S
AD  - Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Aghamohammadi, A
AU  - Aghamohammadi A
FAU - Farshadi, F
AU  - Farshadi F
FAU - Movahedi, M
AU  - Movahedi M
FAU - Parvaneh, N
AU  - Parvaneh N
FAU - Pouladi, N
AU  - Pouladi N
FAU - Moazzami, K
AU  - Moazzami K
FAU - Cheraghi, T
AU  - Cheraghi T
FAU - Mahdaviani, S A
AU  - Mahdaviani SA
FAU - Saghafi, S
AU  - Saghafi S
FAU - Heydari, G
AU  - Heydari G
FAU - Abdollahzade, S
AU  - Abdollahzade S
FAU - Rezaei, N
AU  - Rezaei N
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Bacterial Infections/etiology/immunology/therapy
MH  - Child
MH  - Child, Preschool
MH  - *Desensitization, Immunologic
MH  - Drug Compounding
MH  - Drug-Related Side Effects and Adverse Reactions/*immunology/prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage/*adverse effects
MH  - Immunologic Deficiency Syndromes/complications/immunology/*therapy
MH  - Infant
MH  - Infusions, Intravenous
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Opportunistic Infections/etiology/immunology/therapy
MH  - Quality of Life
EDAT- 2009/05/30 09:00
MHDA- 2009/07/25 09:00
CRDT- 2009/05/30 09:00
PHST- 2009/05/30 09:00 [entrez]
PHST- 2009/05/30 09:00 [pubmed]
PHST- 2009/07/25 09:00 [medline]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 2009;19(2):139-45.